

# Hepatitis

#### Objectives

- 1. Understand the classification of viral hepatitis
- 2. Recognize the global burden, epidemiology and risk factors of viral hepatitis infection
- 3. Enumerate modes of transmission of different serotypes
- 4. Provides measures of prevention and control
- 5. Recognize the epidemiology, burden of disease and national measures to prevent spread of viral hepatitis in KSA

Resources Dr. Shatha Alduraywish slides and notes

Done by: Team Members: Ashwaq Almajed , Meshal aleiaidi, Abdulmohsen alghannam

Team Leaders: Mohammed Ghandour , Ghadah Almuhana

Revised by: Basel almeflh

Editing file | feedback


Important | extra | notes



#### **Introduction to Hepatitis**

#### What Is Hepatitis?

An inflammation of the liver



### +Toxins and some herbal substance may cause hepatitis

### **Viral Hepatitis**

- Infection of the liver caused by any type of viruses.
- Past > Hepatitis A virus (HAV) and hepatitis B virus (HBV) were the only known aetiological agents of viral hepatitis
- Present > Hepatitis viruses C, D, E and G have also been identified and are recognized as aetiological agents of viral hepatitis
- Other causative viruses like cytomegalovirus (CMV), Epstein- Barr virus, yellow fever virus and rubella virus (less common, but may cause hepatitis in immunocompromised people)

#### WHO Global Hepatitis Report 2017:

- Viral hepatitis caused 1.34 million deaths in 2015
- Most viral hepatitis deaths in 2015 were due to <u>chronic liver disease</u> (liver cirrhosis ) and <u>primary liver cancer</u> (hepatocellular carcinoma)
- Globally, in 2015,
  - 257 million people were living with chronic HBV infection
  - 71 million people with chronic HCV infection.

# **Hepatitis** A

• Acute infectious disease caused by hepatitis A virus (HAV).

(Never Chronic!, except 5% of those who have other medical conditions)

- Symptoms
  - Non specific symptoms (Fever\*, chills, headache,fatigue, generalized weakness and pains)
  - Followed by (anorexia, nausea, vomiting, dark urine and jaundice\*\*).

#### \* fever is mainly with HAV, rare with HBV HCV

\*\* jaundice is very imp. symptoms for hepatitis bc it is more specific

- Mode of transmission
  - Fecal-oral route (how to prevent it? by improving hygiene)

# **Global Burden of HAV**

#### endemic in most developing countries

WHO estimates that worldwide, hepatitis A caused approximately 11 000 deaths in 2015 (accounting for 0.8% of the mortality from viral hepatitis).


#### we divide areas into 3 parts:

1- high level of infection ( developing countries ) = have higher immunity ( because some cases will be asymptomatic and they have Antibodies against the infection, so they are immunized indirectly).

- 2- intermediate ( between developing and developed countries ) = have higher infection rate
- 3- developed countries = low infection ( because of high hygiene and preventive measures )


# **Prevalence of HAV in USA**

Hepatitis A rates in the United States have declined by more than 95% since hepatitis A vaccine first became available in 1995.





#### **Epidemiological determinants of HAV**



**Incubation Period** 

- 14-28 days. ( short IP)
- The length of the incubation period is proportional to the dose of the virus ingested. (as the dose increase the IP increases )

#### **Clinical spectrum**

Hepatitis A resolves completely in 98 % of cases but relapse of symptoms are noted in 3- 20 % of cases

Prevention and Control		
Control of reservoir	<ul> <li>Control of reservoir is difficult because of:</li> <li>Faecal shedding of the virus is at its height during the incubation period and early phase of illness</li> <li>The occurrence of large number of subclinical cases</li> <li>Strict isolation of cases is not a useful control measure (bc infection may occur before symptoms appear)</li> </ul>	
Control of transmission	<ul> <li>The best means of reducing the spread of infection is by</li> <li>Promoting simple measures of personal and community hygiene</li> <li>Hand washing before eating and after toilet</li> <li>The sanitary disposal of excreta which will prevent contamination of water, food and milk</li> <li>Proper disposal of sewage within communities.</li> </ul>	
Control of susceptible population	<ul> <li>Targeted protection of high-risk groups e.g. travellers to areas of intermediate or high endemicity.</li> <li>Universal Vaccine(for infants too).*</li> <li>Human immunoglobulin.</li> </ul>	

#### Vaccines

Types of hepatitis A vaccines:

Formaldehyde inactivated vaccines	Live attenuated vaccines
<ul> <li>Safe after the age of 12 months</li> <li>The complete vaccination schedule consists of 2 dose administration into the deltoid muscle</li> <li>The interval between the first (primary) dose and second (booster) dose is commonly 6-12 months (18–36 months)</li> <li>It can be administered simultaneously with other vaccines</li> <li>Following 2 doses of vaccine the protective efficacy is about 94%</li> <li>mostly used in KSA</li> </ul>	• The live attenuated vaccine is administered as a single subcutaneous dose.

**In Summary** 

Hepatitis A causes only acute hepatitis.


HAV is transmitted mostly through exposure to contaminated food or water, or through exposure to infected persons.

A safe and effective vaccine is available.

#### Hepatitis **B**

- Blood-borne infection
- Usually, it is an acute infection, which may be either subclinical or symptomatic.
- In approximately 5 to 15% of cases, HBV infection fails to resolve and the affected individuals then become persistent carriers of the virus (presence of HBsAg for > 6 months)
- Persistent HBV infection may cause progressive liver disease including chronic active hepatitis and hepatocellular carcinoma
- In 2015, the global prevalence of HBV infection in the general population was 3.5%
- Prevalence was the highest in the African (6.1%) and Western Pacific regions (6.2%)
- Adults chronically infected may include 65 million women of childbearing age\* who can potentially transmit HBV to their babies

\*this is why the prevalence of HBV is still high



Agent Factor	
Agent	<ul> <li>The hepatitis B virus</li> <li>It multiplies in liver cells.</li> </ul>
RESERVOIR OF INFECTION	<ul> <li>The human cases are the only reservoir of infection.</li> <li>Persistent carrier defined as the presence of HBsAg for more than 6 months</li> </ul>
PERIOD OF INFECTIVITY	<ul> <li>The virus is present in the blood during the incubation period (for a month before jaundice) and acute phase of the disease.</li> <li>Period of communicability is usually several months or until disappearance of HBsAg and appearance of surface antibody.</li> </ul>
INFECTIVE MATERIAL	<ul> <li>Contaminated blood is the main source of infection</li> <li>body secretions such as saliva, vaginal secretions and semen of infected person</li> </ul>

Host Factors	
AGE	<ul> <li>The outcomes of HBV infection are age-dependent</li> <li>The development of chronic HBV infection is inversely related to age         <ul> <li>80-90% of persons infected perinatally</li> <li>30% infected in early childhood (less than 6 years of age)</li> <li>5 % infected after 6 years of age</li> </ul> </li> </ul>
Hepatitis B and HIV infection:	• It is estimated that 10% of the 40 million people infected with HIV worldwide are coinfected with HBV.
HIGH-RISK GROUPS:	<ul> <li>Recipients of blood transfusions</li> <li>Health care workers</li> <li>Laboratory personnel</li> <li>Percutaneous drug abusers</li> <li>Infants of HBV carrier mothers</li> <li>Recipients of solid organ transplants</li> <li>patients who are immunocompromised</li> </ul>

#### **Mode of Transmission**

#### 1. Parenteral route

- Transfusions
- Dialysis
- Contaminated syringes and needles , Pricks of skin
- Handling of infected blood

#### 2. Perinatal transmission

- Spread of infection from HBV carrier mothers to their babies (at time of delivery, thats why we give HBV vaccine(and immunoglobulin) given within 24 hours after delivery) \*
- The majority of children born to mothers who are HBeAg- positive become **chronically** infected
- 3. Sexual transmission

#### **Incubation Period**

- It is clinically characterized by a tendency to a long incubation period
- Usually 30 to 180 days (average 75 days) (one moths 6 months )
- Lower doses of the virus result often longer incubation period. (opposite to HAV)

# **Prevention and Control**

- Since there is no specific treatment, prevention has been the major aim in managing viral hepatitis B.
- General preventive measures:
  - All blood donors should be screened for HBV infection
  - **Health Care workers** should be alerted to the importance of adequate sterilization of all instruments and to the practice of simple hygienic measures
  - **Carriers** should be told not to share toothbrushes and use barrier methods of contraception; they should not donate blood

#### **Hepatitis B Vaccine**

- The recommended schedule for vaccination is a 4 dose schedule where the dose at birth is followed by three additional doses at 2, 4 and 6 months with DPT vaccination.
- These doses may be given either as monovalent vaccine or as a combination (eg. With DPT and/or Hib)
- The minimum **recommended interval** between the doses is 4 weeks.

#### Immunization in adults


- Routine pre-exposure vaccination should be considered for high risk group
- The usual schedule for adults is 2 doses separated by no less than 4 weeks, and a third dose 4 to 6 months after the second dose

Hepatitis C	• Hepatitis C is a contagious liver disease that results from infection with the hepatitis C virus.	
Route of transmission:	<ul> <li>The HCV is most commonly transmitted through exposure to infectious blood         <ul> <li>Receipt of contaminated blood transfusions, blood products and organ transplants</li> <li>Injections given with contaminated syringes and needle-stick injuries in health-care settings</li> <li>Injection drug use</li> <li>Born to a hepatitis C-infected mother</li> </ul> </li> <li>Sexual transmitted route</li> </ul>	
Burden of Hepatitis C	<ul> <li>Every year, 3-4 million people are infected with the HCV.</li> <li>About 130-150 million people are chronically infected and are at risk of developing liver cirrhosis and/or liver cancer.</li> <li>More than 500,000 people die from hepatitis C - related liver diseases every years.</li> <li>About 75-85% of newly infected persons develop chronic disease (it is more dangerous than HBV bc high chance it will be chronic )</li> <li>60- 70% of chronically infected people develop chronic liver disease; 5-20% develop cirrhosis and 1-5% die from cirrhosis or liver cancer.</li> <li>In 25% of liver cancer patients, the underlying cause is hepatitis C.</li> <li>HCV has treatment unlike HBV.</li> </ul>	
Incubation Period	<ul> <li>The incubation period for hepatitis C is 2 weeks to 6 months. (same as HBV)</li> <li>Prevention and Control</li> </ul>	
Prevention and control: the main preventive measures for hepatitis C is Screening of blood donors		
primary	<ul> <li>There is no vaccine for hepatitis C.</li> <li>The risk of infection can be reduced by avoiding:         <ul> <li>unnecessary and unsafe injections;</li> <li>unsafe blood products;</li> <li>unsafe sharps waste collection and disposal</li> <li>use of illicit drugs and sharing of injection equipment</li> <li>unprotected sex with hepatitis C-infected people</li> <li>sharing of sharp personal items that may be contaminated with infected blood</li> <li>tattoos, piercings and acupuncture performed with contaminated equipment.</li> </ul> </li> </ul>	
Secondary and tertiary prevention	<ul> <li>For people infected with the HCV, WHO recommends:</li> <li>Education and counselling on options for care and treatment</li> <li>Immunization with the hepatitis A and B vaccines to prevent coinfection from these hepatitis viruses. why ? to prevent further damage to hepatocyte</li> <li>Early and appropriate medical management including antiviral therapy if appropriate</li> <li>Regular monitoring for early diagnosis of chronic liver disease.</li> </ul>	


# Hepatitis in Saudi Arabia

- In 2007, the Saudi Ministry of Health (MOH) ranked viral hepatitis as the second most common viral disease after chickenpox, with almost 9000 new cases diagnosed in that year (52% HBV, 32% HCV, and 16% HAV).
- A steady decline in prevalence of all 3 common hepatotropic viruses during the past 3 decades due to:
  - $\circ$  better living conditions
  - Universal blood bank screening
  - Increased awareness of safe social and clinical practices]=
  - Implementation of childhood immunization against hepatitis B virus (HBV).

Prevalence of HBsAg among the Saudi population documented before and after introducing a nation-wide HBV vaccination program, over an 18-year period



# • this study shows that immunization is very effective in reducing the prevalence of HBV





# THE END

